Search Results

Sexton , Denise Wootten , et al., for their work on Isoquinoline small molecule ligands are agonists

Denise Wootten and colleagues has highlighted the importance of extracellular loop 2 (ECL2) in stabilizing Wootten, D., et al., The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased

Decisions stall. And momentum quietly dies. GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide. you move faster—with fewer blind spots, tighter execution, and a clear line of sight to your next key decision teams don’t need more data— they need clarity ✅ Yamina’s Corner helps teams move from data chaos to decisive

the frameworks needed to interpret data correctly, eliminate wasted effort, and accelerate confident decisions

crafted for pharmacologists and biotech scientists who need to translate mechanistic nuance into better decision-making Map dynamic receptor behavior to real-time decision-making.   Sharpen your discovery decisions ➤ GPCR Signal Transduction Call for Papers: Define What Comes Next Volume GPCRs across translational pharmacology, drug development, or molecular pharmacology, this is your decision GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

equilibrium curves are your comfort zone, this week’s feature will challenge (and strengthen) your decisions conformation of GLP‑1 receptor Terry's Corner – Advanced Applications of GPCR Kinetics for Real-World Decision These are the pattern-recognition tools that convert uncertainty into decisions you can defend at a project GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

research requires turning data into insights for drug discovery Hi GPCR Friends, Every week, critical decisions statistical tests actually answer the question you think you’re asking—so you can start making confident decisions GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Wootten, D., et al., Allostery and Biased Agonism at Class B G Protein-Coupled Receptors.  

 in tissues like tumors slows offset and improves therapeutic window ✅ Examples of how rebinding in dense And when receptors are dense (like GPCRs on membranes), this rebinding hits the collisional limit , where down how to distinguish between true target persistence vs. sequestration, with clear takeaways for decision-making

insight designed to equip you to move beyond surface-level affinity data and make faster, more confident decisions Why Faster, Smarter Decisions Require More Than Kd In drug discovery today, the clock is always ticking Your pipeline depends on early, well-informed decisions that move promising candidates forward while of endogenous ligands— change kinetic behavior , and ignoring this can lead to wrong prioritization decisions Kenakin’s lecture guides you through key questions that should shape your decision-making process: Are

And when decisions ride on subtle shifts, “looks different” isn’t good enough. No more guesswork, only decisions you can trust. This ability transforms meetings from endless discussions to clear decisions. —becomes a black-and-white decision. Does Your Assay Agree With the Literature? s Corner Why Terry’s Corner Your work demands clarity, speed, and confidence, especially when early decisions

binding experiments that advance your work efficiently ✅ Clarity that helps you move from assay to decision you’re working in drug discovery, you know the pressure: timelines are tight, resources finite, and decisions happening in a physiological context, and misunderstanding this can introduce inefficiency into your decision-making Interpret complex binding data correctly Separate what matters from what misleads Make confident, efficient decisions

questions about binding kinetics and experimental constraints, ensuring your analysis is robust and your decisions Sharpen your discovery decisions ➤ Yamina's Consulting Corner - Building Your GPCR Program for Breakthroughs Bridge science and strategy:  Ensure data and decision-making align with funding and milestones. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who GPCR Premium Today The breakthroughs are happening now, and the decisions you make today will determine

This week’s edition links ligand mechanism to the decisions that shape affinity, efficacy, selectivity Each week we highlight the decisions that move GPCR projects forward—from pharmacology essentials to Win on kinetics, not just Kd:  Dynamic binding means “affinity” moves—design readouts and decisions that GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need Your team’s next good decision may start here 🚀 Join Premium Today & Enjoy ➤ 🎓 Full GPCR University

Community, If you work on GPCR discovery, you already know: early signals can mislead, and timing your next decision Terry Kenakin to elevate your science and sharpen your decisions. relevance:  Fluorescent ligands can retain receptor integrity—critical when signaling readouts drive decisions vetted job opportunities, and insider commentary—structured to help you move faster and make cleaner decisions pharmacology." — DrGPCR University Attendee Ready to turn ambiguous signals into confident, defensible decisions—and

In fact, her early decisions were based on curiosity, instinct, and a surprising love of cooking (yes Choosing not to overthink major career decisions, because as she puts it:  “A lot of friends of mine

You’ll get a framework to predict duration, penetration, and PK/PD separation—so decisions move faster Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models into decisions It’s an operating system for discovery decisions, featuring practical frameworks, trusted curations, GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Welcome GPCR Fans,   Every discovery-phase decision you make shapes your entire pipeline trajectory—and Available only in Terry’s Corner - Premium Members get an exclusive discount Sharpen your discovery decision Rethink translational success:  How post-COVID insights and unconventional decision-making shaped Serafini GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who Don’t Fall Behind—Access the Edge You Need 👉 Ready to sharpen your discovery decisions?

Decisions are slow, crucial data is siloed, and despite everyone working hard, programs drift. Delays in critical go/no-go decisions. Frustrated teams and slipping timelines. You can't move fast without clarity, and you can't make confident decisions without robust structure.

This Week’s GPCR Intelligence: If you want cleaner decisions, start with the system—then the ligand. This isn’t academic—it’s a pipeline filter for reality-aligned decisions. clarity—so you can pick better targets, stress-test hypotheses earlier, and focus on experiments that change decisions GPCR scientists, translational pharmacologists, discovery teams, and decision-makers who need fast, curated

But here’s the truth: too many programs still fail because early decisions were built on shaky mechanistic Perspective:  Why this knowledge reshapes dose–response interpretation and informs your pipeline’s next decision The result is not just cleaner assay design but a sharper decision framework for selecting, prioritizing In drug discovery, orthosteric vs. allosteric isn’t just a mechanistic detail; it’s a decision that shapes

Sharpen your discovery decisions ➤ Yamina’s Corner - The Hidden Cost of Busy A GPCR program can collapse—not Yamina’s Corner reveals how fragmented data, undefined workflows, and ambiguous decision gates silently GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

It’s about a dynamic dance of chemical forces, equilibrium shifts, and molecular decisions that determine It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects

With a biology-first strategy, embedded execution, and scalable systems, it turns scattered data into decisions Better pharmacology leads to better decisions—unlock it now with Terry’s Corner.

latest and best assay; it's about the framework that ensures the right assay data leads to the right decision building your Precision Blueprint , ensuring every scientific detail, operational process, and strategic decision Disconnect : Discover how fragmented, unmanaged GPCR data  cripples scientific progress and strategic decision-making

No more blind spots, only decisions rooted in reality. You’ll know how to use  kinetics to sharpen decisions: Confirm whether your system has truly equilibrated Make decisions with confidence. 🟢 40 years of expertise at your fingertips: Explore the complete library

We're launching with 10 on-demand lessons , each featuring:   A short, focused video A concise written Explore Terry's Corner Better decisions start with better pharmacology.

feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions It’s built for scientists and teams who want fewer tabs and faster decisions—one scroll that blends structure GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

today and get direct access to decades of pharmacology experience that turn complex systems into better decisions Here’s what you’ll get: Weekly expert sessions  that turn messy data into clear decisions On-demand access Make decisions with confidence. 🟢 40 years of expertise at your fingertips: Explore the complete library

And here’s the danger: if you can’t tell how  a drug is working, every downstream decision—SAR, lead You’ll know how to use them to sharpen discovery decisions. pharmacologists refining fundamentals, scientists challenging legacy assumptions, and leaders who need decision-ready